相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy
Alberto Bartesaghi et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Jean-Philippe Julien et al.
SCIENCE (2013)
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Dmitry Lyumkis et al.
SCIENCE (2013)
Trimeric, Coiled-coil Extension on Peptide Fusion Inhibitor of HIV-1 Influences Selection of Resistance Pathways
Min Zhuang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket
Xiaowen Yu et al.
JOURNAL OF VIROLOGY (2012)
HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug
Opass Putcharoen et al.
JOURNAL OF VIROLOGY (2012)
Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2012)
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
Youdong Mao et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors
Christopher J. De Feo et al.
VIRUSES-BASEL (2012)
Is there a future for antiviral fusion inhibitors?
Ben Berkhout et al.
CURRENT OPINION IN VIROLOGY (2012)
In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor
Zhonghua Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2011)
Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41
Wei Wang et al.
JOURNAL OF VIROLOGY (2011)
Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat
Kazuki Izumi et al.
ANTIVIRAL RESEARCH (2010)
Development of Peptide and Small-Molecule HIV-1 Fusion Inhibitors that Target gp41
Lifeng Cai et al.
CHEMMEDCHEM (2010)
Rational antibody-based HIV-1 vaccine design: current approaches and future directions
Laura M. Walker et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Inhibition of HIV-1 by Fusion Inhibitors
Dirk Eggink et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors
Kazuya Shimura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Kosuke Miyauchi et al.
CELL (2009)
Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors
Dirk Eggink et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Mutations in gp120 Contribute to the Resistance of Human Immunodeficiency Virus Type 1 to Membrane-Anchored C-Peptide maC46
Felix G. Hermann et al.
JOURNAL OF VIROLOGY (2009)
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2009)
Early Steps of HIV-1 Fusion Define the Sensitivity to Inhibitory Peptides That Block 6-Helix Bundle Formation
Kosuke Miyauchi et al.
PLOS PATHOGENS (2009)
Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
Kristen M. Kahle et al.
PLOS PATHOGENS (2009)
Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure
Xuefang Bai et al.
BIOCHEMISTRY (2008)
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2008)
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K)
Martin Tolstrup et al.
AIDS (2007)
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Jing Lu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy
E Poveda et al.
JOURNAL OF CLINICAL VIROLOGY (2005)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides
S Lohrengel et al.
JOURNAL OF VIROLOGY (2005)
Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
JD Reeves et al.
JOURNAL OF VIROLOGY (2005)
Human immunodeficiency virus (HIV) gp41 escape mutants: Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120
E Desmezieres et al.
JOURNAL OF VIROLOGY (2005)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp4l and rev-responsive element functions
D Nameki et al.
JOURNAL OF VIROLOGY (2005)
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle
LG Abrahamyan et al.
JOURNAL OF VIROLOGY (2005)
Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
T Matthews et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
PR Sista et al.
AIDS (2004)
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment
S Menzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
CE Baldwin et al.
JOURNAL OF VIROLOGY (2004)
The HIV Env-mediated fusion reaction
SA Gallo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2003)
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope
NR Kilgore et al.
JOURNAL OF VIROLOGY (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites
Y He et al.
JOURNAL OF VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
M Cavrois et al.
NATURE BIOTECHNOLOGY (2002)
Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41
CA Bewley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process
SA Gallo et al.
BIOCHEMISTRY (2001)
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
DM Eckert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Design and properties of NCCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity
JM Louis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Protein design of an HIV-1 entry inhibitor
MJ Root et al.
SCIENCE (2001)
分享论文
